Literature DB >> 12719595

Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.

David A Price1, George Scullard, Annette Oxenius, Ruth Braganza, Simon A Beddows, Shamim Kazmi, John R Clarke, Gabriele E Johnson, Jonathan N Weber, Rodney E Phillips.   

Abstract

Many individuals chronically infected with human immunodeficiency virus type 1 (HIV-1) experience a recrudescence of plasma virus during continuous combination antiretroviral therapy (ART) due either to the emergence of drug-resistant viruses or to poor compliance. In most cases, virologic failure on ART is associated with a coincident decline in CD4(+) T lymphocyte levels. However, a proportion of discordant individuals retain a stable or even increasing CD4(+) T lymphocyte count despite virological failure. In order to address the nature of these different outcomes, we evaluated virologic and immunologic variables in a prospective, single-blinded, nonrandomized cohort of 53 subjects with chronic HIV-1 infection who had been treated with continuous ART and monitored intensively over a period of 19 months. In all individuals with detectable viremia on ART, multiple drug resistance mutations with similar impacts on viral growth kinetics were detected in the pol gene of circulating plasma virus. Further, C2V3 env gene analysis demonstrated sequences indicative of CCR5 coreceptor usage in the majority of those with detectable plasma viremia. In contrast to this homogeneous virologic pattern, comprehensive screening with a range of antigens derived from HIV-1 revealed substantial immunologic differences. Discordant subjects with stable CD4(+) T lymphocyte counts in the presence of recrudescent virus demonstrated potent virus-specific CD4(+) and CD8(+) T lymphocyte responses. In contrast, subjects with virologic failure associated with declining CD4(+) T lymphocyte counts had substantially weaker HIV-specific CD4(+) T lymphocyte responses and exhibited a trend towards weaker HIV-specific CD8(+) T lymphocyte responses. Importantly the CD4(+) response was sustained over periods as long as 11 months, confirming the stability of the phenomenon. These correlative data lead to the testable hypothesis that the consequences of viral recrudescence during continuous ART are modulated by the HIV-specific cellular immune response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719595      PMCID: PMC154002          DOI: 10.1128/jvi.77.10.6041-6049.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

Review 1.  The CD4(+) T cell response to HIV-1.

Authors:  L J Picker; V C Maino
Journal:  Curr Opin Immunol       Date:  2000-08       Impact factor: 7.486

Review 2.  Cytotoxic T lymphocyte responses to human immunodeficiency virus: control and escape.

Authors:  A K Sewell; D A Price; A Oxenius; A D Kelleher; R E Phillips
Journal:  Stem Cells       Date:  2000       Impact factor: 6.277

3.  Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo.

Authors:  R S Veazey; I C Tham; K G Mansfield; M DeMaria; A E Forand; D E Shvetz; L V Chalifoux; P K Sehgal; A A Lackner
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death.

Authors:  D Lecossier; F Bouchonnet; P Schneider; F Clavel; A J Hance
Journal:  J Infect Dis       Date:  2001-03-08       Impact factor: 5.226

5.  Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes.

Authors:  A Oxenius; D A Price; P J Easterbrook; C A O'Callaghan; A D Kelleher; J A Whelan; G Sontag; A K Sewell; R E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

Review 6.  HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness.

Authors:  B Berkhout
Journal:  J Biomed Sci       Date:  1999 Sep-Oct       Impact factor: 8.410

7.  HIV preferentially infects HIV-specific CD4+ T cells.

Authors:  Daniel C Douek; Jason M Brenchley; Michael R Betts; David R Ambrozak; Brenna J Hill; Yukari Okamoto; Joseph P Casazza; Janaki Kuruppu; Kevin Kunstman; Steven Wolinsky; Zvi Grossman; Mark Dybul; Annette Oxenius; David A Price; Mark Connors; Richard A Koup
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

8.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.

Authors:  R A Fouchier; M Groenink; N A Kootstra; M Tersmette; H G Huisman; F Miedema; H Schuitemaker
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

9.  Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.

Authors:  C A Stoddart; T J Liegler; F Mammano; V D Linquist-Stepps; M S Hayden; S G Deeks; R M Grant; F Clavel; J M McCune
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

10.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

Authors:  S G Deeks; T Wrin; T Liegler; R Hoh; M Hayden; J D Barbour; N S Hellmann; C J Petropoulos; J M McCune; M K Hellerstein; R M Grant
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

View more
  6 in total

1.  Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol.

Authors:  A C Karlsson; J M Chapman; B D Heiken; R Hoh; E G Kallas; J N Martin; F M Hecht; S G Deeks; D F Nixon
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.

Authors:  Steven G Deeks; Becky Schweighardt; Terri Wrin; Justin Galovich; Rebecca Hoh; Elizabeth Sinclair; Peter Hunt; Joseph M McCune; Jeffrey N Martin; Christos J Petropoulos; Frederick M Hecht
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment.

Authors:  Brinda Emu; Elizabeth Sinclair; David Favre; Walter J Moretto; Priscilla Hsue; Rebecca Hoh; Jeffrey N Martin; Douglas F Nixon; Joseph M McCune; Steven G Deeks
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo.

Authors:  Jason M Brenchley; Laura E Ruff; Joseph P Casazza; Richard A Koup; David A Price; Daniel C Douek
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells.

Authors:  Sekar Natesampillai; Zilin Nie; Nathan W Cummins; Dirk Jochmans; Gary D Bren; Jonathan B Angel; Andrew D Badley
Journal:  PLoS Pathog       Date:  2010-11-24       Impact factor: 6.823

6.  Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.

Authors:  Koen K A Van Rompay; Jeffrey A Johnson; Emily J Blackwood; Raman P Singh; Jonathan Lipscomb; Timothy B Matthews; Marta L Marthas; Niels C Pedersen; Norbert Bischofberger; Walid Heneine; Thomas W North
Journal:  Retrovirology       Date:  2007-04-06       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.